Anti-idiotypic antibodies and "tumor-only" antigens: An update

Open Immunology Journal

Volumn 2, Issue 1, 2009, Pages 1-8

  López Requena, Alejandro ^a,b   Burrone, Oscar R ^b  

^a CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

^b INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

Author keywords

Anti idiotypic antibodies; B cell lymphoma; Ganglioside; Idiotype; NeuGc

Indexed keywords

1E10 MONOCLONAL ANTIBODY; AB2 MONOCLONAL ANTIBODY; ANTIIDIOTYPIC ANTIBODY; ANTINEOPLASTIC AGENT; CANCER VACCINE; DNA VACCINE; GANGLIOSIDE ANTIBODY; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; IMMUNOGLOBULIN G2B; IMMUNOGLOBULIN M ANTIBODY; KEYHOLE LIMPET HEMOCYANIN; MONOCLONAL ANTIBODY; NEUAC GD2 GANGLIOSIDE MONOCLONAL ANTIBODY; NEUGC GM3; TRASTUZUMAB; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; AUTOIMMUNE DISEASE; B CELL LYMPHOMA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; CYTOFLUOROMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNE RESPONSE; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; NEUROBLASTOMA; NONHODGKIN LYMPHOMA; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW;

EID: 77953373333     PISSN: None     EISSN: 18742262     Source Type: Journal    
DOI: 10.2174/1874226200902010001     Document Type: Review

References (95)

1. Oudin J, Michel M. Une nouvelle forme d'allotypie des globulines du serum de lapin, apparemment liée à la foction et à la spécificité des anticorps. C R Acad Sci (Paris) 1963; 275: 805-808
2. Grey HM, Mannik M, Kunkel HG. Individual antigenic specificity of myeloma proteins. Characteristics and localization to subunits. J Exp Med 1965; 121: 561-575
3. Jerne NK. Towards a network theory of the immune system. Ann Immunol Paris 1974; 125C: 373-389
4. Bona CA, Heber-Katz E, Paul WE. Idiotype-anti-idiotype regulation. I. Immunization with a levan-binding myeloma protein leads to the appearance of auto-anti-(anti-idiotype) antibodies and to the activation of silent clones. J Exp Med 1981; 153: 951-967
5. Coutinho A. The network theory: 21 years later. Scand J Immunol 1995; 42: 3-8.
6. Hernandez AM, Rodriguez M, Lopez-Requena A, Beausoleil I, Perez R, Vazquez AM. Generation of anti-Neu-glycolylganglioside antibodies by immunization with an anti-idiotype monoclonal antibody: A self versus non-self matter. Immunobiology 2005; 210: 11-21. (Pubitemid 40862456)
7. de Cerio AL, Zabalegui N, Rodriguez-Calvillo M, Inoges S, Bendandi M. Anti-idiotype antibodies in cancer treatment. Oncogene 2007; 26: 3594-3602 (Pubitemid 46842706)
8. Irie RF, Irie K, Morton DL. A membrane antigen common to human cancer and fetal brain tissues. Cancer Res 1976; 36: 3510-3517
9. Portoukalian J, Zwingelstein G, Dore J. Lipid composition of human malignant melanoma tumors at various levels of malignant growth. Eur J Biochem 1979; 94: 19-23. (Pubitemid 9236187)
10. Livingston PO, Hood C, Krug LM, et al. Selection of GM2, fucosyl GM1, globo H and polysialic acid as targets on small cell lung cancers for antibody mediated immunotherapy. Cancer Immunol Immunother 2005; 54: 1018-1025
11. Bhattacharya-Chatterjee M, Chatterjee SK, Foon KA. Anti-idiotype vaccine against cancer. Immunol Lett 2000; 74: 51-58
12. Chapman PB, Houghton AN. Induction of IgG antibodies against GD3 ganglioside in rabbits by an anti-idiotypic monoclonal antibody. J Clin Invest 1991; 88: 186-192
13. Chapman PB. Vaccinating against GD3 ganglioside using BEC2 anti-idiotypic monoclonal antibody. Curr Opin Investig Drugs 2003; 4: 710-715 (Pubitemid 36916712)
14. Giaccone G, Debruyne C, Felip E, et al. Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study). J Clin Oncol 2005; 23: 6854-6864
15. Uttenreuther-Fischer MM, Krüger JA, Fischer P. Molecular characterization of the anti-idiotypic immune response of a relapse-free neuroblastoma patient following antibody therapy: a possible vaccine against tumors of neuroectodermal origin? J Immunol 2006; 176: 7775-7786
16. Mueller BM, Romerdahl CA, Gillies SD, Reisfeld RA. Enhancement of antibody-dependent cytotoxicity with a chimeric anti-GD2 antibody. J Immunol 1990; 144: 1382-1386 (Pubitemid 20072910)
17. Varki A. N-glycolylneuraminic acid deficiency in humans. Biochimie 2001; 83: 615-622 (Pubitemid 32821225)
18. Shaw L, Schauer R. The biosynthesis of N-glycoloylneuraminic acid occurs by hydroxylation of the CMP-glycoside of N-acetylneuraminic acid. Biol Chem Hoppe Seyler 1988; 369: 477-486 (Pubitemid 18166423)
19. Chou HH, Takematsu H, Díaz S, et al. A mutation in human CMP-sialic acid hydroxylase occurred after the Homo-Pan divergence. Proc Natl Acad Sci USA 1998; 95: 11751-11756
20. Irie A, Suzuki A. CMP-N-acetylneuraminic acid hydroxilase is exclusively inactive in humans. Biochem Biophys Res Comun 1998; 248: 330-333 (Pubitemid 28386421)
21. Olson MV, Varki A. Sequencing the chimpanzee genome: insights into human evolution and disease. Nat Rev Genet 2003; 4: 20-28 (Pubitemid 36043212)
22. Marquina G, Waki H, Fernández LE, et al. Gangliosides expressed in human breast cancer. Cancer Res 1996; 56: 5165-5171
23. Malykh YN, Schauer R, Shaw L. N-Glycolylneuraminic acid in human tumours. Biochimie 2001; 83: 623-634 (Pubitemid 32821226)
24. Kannagi R, Yin J, Miyazaki K, Izawa M. Current relevance of incomplete synthesis and neo-synthesis for cancer-associated alteration of carbohydrate determinants-Hakomori's concepts revisited. Biochim Biophys Acta 2008; 1780: 525-531
25. Tangvoranuntakul P, Ganneux P, Díaz S, et al. Human uptake and incorporation of an immunogenic nonhuman dietary sialic acid. Proc Natl Acad Sci USA 2003; 100: 12045-12050
26. Bardor M, Nguyen DH, Díaz S, Varki A. Mechanism of uptake and incorporation of the non-human sialic acid N-glycolylneuraminic acid into human cells. J Biol Chem 2005; 280: 4228-4237 (Pubitemid 40288589)
27. Yin J, Hashimoto A, Izawa M, et al. Hypoxic culture induces expression of sialin, a sialic acid transporter, and cancer-associated gangliosides containing non-human sialic acid on human cancer cells. Cancer Res 2006; 66: 2937-2945
28. de Leon J, Fernandez A, Mesa C, Clavel M, y Fernandez, LE. Role of tumour-associated N-glycolylated variant of GM3 ganglioside in cancer progression: effect over CD4 expression on T cells. Cancer Immunol Immunother 2006; 55: 443-450
29. de Leon J, Fernandez A, Clavell M, et al. Differential influence of the tumour-specific non-human sialic acid containing GM3 ganglioside on CD4+CD25- effector and naturally occurring CD4+CD25+ regulatory T cells function. Int Immunol 2008; 20: 591-600.
30. Potapenko M, Shurin GV, de Leon J. Gangliosides as immunomodulators. Adv Exp Med Biol 2007; 601: 195-203.
31. Vazquez AM, Alfonso M, Lanne B, et al. Generation of a murine monoclonal antibody specific for N-glycolylneuraminic acidcontaining gangliosides that also recognizes sulfated glycolipids. Hybridoma 1995; 14: 551-556
32. Moreno E, Lanne B, Vazquez AM, et al. Delineation of the epitope recognized by an antibody specific for N-glycolylneuraminic acid-containing gangliosides. Glycobiology 1998; 8: 695-705.
33. Vazquez AM, Perez A, Hernandez AM, et al. Syngeneic antiidiotypic monoclonal antibodies to an anti-NeuGc-containing ganglioside monoclonal antibody. Hybridoma 1998; 17: 527-534
34. Lopez-Requena A, Rodriguez M, de Acosta CM, et al. Gangliosides, Ab1 and Ab2 antibodies II. Light versus heavy chain: An idiotype-anti-idiotype case study. Mol Immunol 2007; 44: 1015-1028
35. Fernandez LE, Alonso DF, Gomez DE, Vazquez AM. Ganglioside-based vaccines and anti-idiotype antibodies for active immunotherapy against cancer. Expert Rev Vaccines 2003; 2: 89-95. (Pubitemid 37541567)
36. Alfonso M, Diaz A, Hernandez AM, et al. An anti-idiotype vaccine elicits a specific response to N-glycolyl sialic acid residues of glycoconjugates in melanoma patients. J Immunol 2002; 168: 2523-2529
37. Diaz A, Alfonso M, Alonso R, et al. Immune responses in breast cancer patients immunized with an anti-idiotype antibody mimicking NeuGc-containing gangliosides. Clin Immunol 2003; 107: 80-89
38. Guthmann MD, Castro M, Cinat G, et al. Cellular and humoral anti-ganglioside response after prolonged anti-idiotypic immunotherapy in breast cancer patients. J Immunother 2006; 29: 215-223
39. Neninger E, Diaz RM, de la Torre A, et al. Active immunotherapy with 1E10 anti-idiotype vaccine in patients with small cell lung cancer: report of a phase I trial. Cancer Biol Ther 2007; 6: 145-150
40. Hernandez AM, Toledo D, Martinez D, et al. Characterization of the antibody response against NeuGcGM3 ganglioside elicited in non-small cell lung cancer patients immunized with an anti-idiotype antibody. J Immunol 2008; 181: 6625-6634
41. Carr A, Mullet A, Mazorra Z, et al. A mouse IgG1 monoclonal antibody specific for N-glycolyl GM3 ganglioside recognized breast and melanoma tumors. Hybridoma 2000; 19: 241-247
42. Carr A, Mesa C, Arango MC, Vazquez AM, Fernandez LE. In vivo and in vitro anti-tumor effect of 14F7 monoclonal antibody. Hybrid Hybridomics 2002; 21: 463-468
43. Roque-Navarro L, Chakrabandhu K, de León J, et al. Anti-ganglioside antibody-induced tumor cell death by loss of membrane integrity. Mol Cancer Ther 2008; 7: 2033-2041
44. Alfonso S, Diaz RM, de la Torre A, et al. 1E10 Anti-Idiotype Vaccine in Non-Small Cell Lung Cancer: Experience in Stage IIIb/IV Patients. Cancer Biol Ther 2007; 6: 1847-1852
45. Benvenuti F, Cesco-Gaspere M, Burrone OR. Anti-idiotypic DNA vaccines for B-cell lymphoma therapy. Front Biosci 2002; 7: d228-34.
46. Benvenuti F, Burrone OR. Genetic vaccination for the immunotherapy of B-cell malignancies. Curr Gene Ther 2002; 2: 235-242
47. Dermime S, Gilham DE, Shaw DM, et al. Vaccine and antibody-directed T cell tumour immunotherapy. Biochim Biophys Acta 2004; 1704: 11-35.
48. Dermime S, Aljurf MD. Current advances, problems and prospects for vaccine-based immunotherapy in follicular non-Hodgkin's lymphoma. Leuk Lymphoma 2005; 46: 497-507. (Pubitemid 40584865)
49. Popescu MC, Robb RJ, Batenjany MM, et al. A novel proteoliposomal vaccine elicits potent antitumor immunity in mice. Blood 2007; 109: 5407-5410
50. Neelapu SS, Gause BL, Harvey L, et al. A novel proteoliposomal vaccine induces antitumor immunity against follicular lymphoma. Blood 2007; 109: 5160-5163
51. Gururajan M, Jennings CD, Bondada S. Cutting edge: constitutive B cell receptor signaling is critical for basal growth of B lymphoma. J Immunol 2006; 176: 5715-5719
52. Yañez R, Barrios Y, Cabrera R, Diaz-Espada F. Intraclonal variability of VH genes in follicular lymphoma patients who have received anti-idiotypic immunotherapy. J Immunother 2006; 29: 61-66 (Pubitemid 43756082)
53. Yañez R, Barrios Y, Ruiz E, Cabrera R, Diaz-Espada F. Anti-idiotypic Immunotherapy in Follicular Lymphoma Patients: Results of a Long Follow-up Study. J Immunother 2008; 31: 310-312
54. Weng WK, Czerwinski D, Timmerman J, Hsu FJ, Levy R. Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. J Clin Oncol 2004; 22: 4717-4724 (Pubitemid 41185081)
55. Weng WK, Czerwinski D, Levy R. Humoral immune response and immunoglobulin G Fc receptor genotype are associated with better clinical outcome following idiotype vaccination in follicular lymphoma patients regardless of their response to induction chemotherapy. Blood 2007; 109: 951-953 (Pubitemid 46220638)
56. Wu J, Edberg JC, Redecha PB, et al. A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J Clin Invest 1997; 100: 1059-1070
57. Koene HR, Kleijer M, Algra J, et al. Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood 1997; 90: 1109-1114
58. Amigorena S, Bonnerot C. Fc receptors for IgG and antigen presentation on MHC class I and class II molecules. Semin Immunol 1999; 11: 385-390 (Pubitemid 30047500)
59. Kalergis AM, Ravetch JV. Inducing tumor immunity through the selective engagement of activating Fcgamma receptors on dendritic cells. J Exp Med 2002; 195: 1653-1659 (Pubitemid 34666079)
60. Moshitzky S, Kukulansky T, Haimovich J, Hollander N. Growth inhibition of myeloma cells by anti-idiotype antibodies in the absence of membrane-bound immunoglobulin. Immunol Cell Biol 2008; 86: 261-267
61. Hurvitz SA, Timmerman JM. Recombinant, tumour-derived idiotype vaccination for indolent B cell non-Hodgkin's lymphomas: a focus on FavId. Expert Opin Biol Ther 2005; 5: 841-852 (Pubitemid 40873892)
62. Reinis M. Drug evaluation: FavId, a patient-specific idiotypic vaccine for non-Hodgkin's lymphoma. Curr Opin Mol Ther 2007; 9: 291-298 (Pubitemid 46944321)
63. Oudejans JJ, Muris JJ, Cillessen SA, Meijer CJ. T-cell response in B-cell lymphomas: favorable or unfavorable? Clin Cancer Res 2008; 14: 2514.
64. Chang KC, Jones D. Reply to the Letter to the Editor from Oudejans et al. Clin Cancer Res 2008; 14: 2515.
65. Muris JJ, Meijer CJ, Cillessen SA, et al. Prognostic significance of activated cytotoxic T-lymphocytes in primary nodal diffuse large B-cell lymphomas. Leukemia 2004; 18: 589-596
66. Hasselblom S, Sigurdadottir M, Hansson U, Nilsson-Ehle H, Ridell B, Andersson PO. The number of tumour-infiltrating TIA-1+ cytotoxic T cells but not FOXP3+ regulatory T cells predicts outcome in diffuse large B-cell lymphoma. Br J Haematol 2007;137: 364-373 (Pubitemid 46650261)
67. Muris JJ, Ylstra B, Cillessen SA, et al. Profiling of apoptosis genes allows for clinical stratification of primary nodal diffuse large Bcell lymphomas. Br J Haematol 2007; 136:38-47.
68. Chang KC, Huang GC, Jones D, Lin YH. Distribution patterns of dendritic cells and T cells in diffuse large B-cell lymphomas correlate with prognoses. Clin Cancer Res 2007; 13: 6666-6672 (Pubitemid 350206802)
69. Zangani MM, Frøyland M, Qiu GY, et al. Lymphomas can develop from B cells chronically helped by idiotype-specific T cells. J Exp Med 2007; 204: 1181-1191
70. Donnelly JJ, Ulmer JB, Shiver JW, Liu MA. DNA vaccines. Annu Rev Immunol 1997; 15: 617-648 (Pubitemid 27169294)
71. Klinman DM. Adjuvant activity of CpG oligodeoxynucleotides. Int Rev Immunol 2006; 25: 135-154 (Pubitemid 44034578)
72. Hemmi H, Takeuchi O, Kawai T, et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000; 408: 740-745
73. Wagner H. The immunobiology of the TLR9 subfamily. Trends Immunol 2004; 25: 381-386 (Pubitemid 38780955)
74. Lopez-Requena A, Bestagno M, Mateo de Acosta C, et al. Gangliosides, Ab1 and Ab2 antibodies III. The idiotype of antiganglioside mAb P3 is immunogenic in a T cell-dependent manner. Mol Immunol 2007; 44: 2915-2922
75. Li E, Pedraza A, Bestagno M, Mancardi S, Sanchez R, Burrone O. Mammalian cell expression of dimeric small immune proteins (SIP). Protein Eng 1997; 10: 731-736 (Pubitemid 27332082)
76. Cesco-Gaspere M, Zentilin L, Giacca M, Burrone OR. Boosting anti-idiotype immune response with recombinant AAV enhances tumour protection induced by gene gun vaccination. Scand J Immunol 2008; 68: 58-66.
77. Liso A, Benedetti R, Fagioli M, Mariano A, Falini B. Modulatory effects of mycobacterial heat-shock protein 70 in DNA vaccination against lymphoma. Haematologica 2005; 90: 60-65 (Pubitemid 40197510)
78. Benvenuti F, Burrone OR, Efremov DG. Anti-idiotypic DNA vaccines for lymphoma immunotherapy require the presence of both variable region genes for tumor protection. Gene Ther 2000; 7: 605-611 (Pubitemid 30175564)
79. Benvenuti F, Burrone OR. Anti-idiotypic antibodies induced by genetic immunisation are directed exclusively against combined V(L)/V(H) determinants. Gene Ther 2001; 8: 1555-1561
80. Cesco-Gaspere M, Benvenuti F, Burrone OR. BCL1 lymphoma protection induced by idiotype DNA vaccination is entirely dependent on anti-idiotypic antibodies. Cancer Immunol Immunother 2005; 54: 351-358 (Pubitemid 40238929)
81. Ullenhag GJ, Spendlove I, Watson NF, et al. A neoadjuvant/adjuvant randomized trial of colorectal cancer patients vaccinated with an anti-idiotypic antibody, 105AD7, mimicking CD55. Clin Cancer Res 2006; 12: 7389-7396
82. Ullenhag GJ, Spendlove I, Watson NF, Kallmeyer C, Pritchard-Jones K, Durrant LG. T-cell responses in osteosarcoma patients vaccinated with an anti-idiotypic antibody, 105AD7, mimicking CD55. Clin Immunol 2008; 128: 148-154
83. Mosolits S, Markovic K, Fagerberg J, et al. T-cell receptor BV gene usage in colorectal carcinoma patients immunised with recombinant Ep-CAM protein or anti-idiotypic antibody. Cancer Immunol Immunother 2005; 54: 557-570
84. Posner MC, Niedzwiecki D, Venook AP, et al. A phase II prospective multi-institutional trial of adjuvant active specific immunotherapy following curative resection of colorectal cancer hepatic metastases: cancer and leukemia group B study 89903. Ann Surg Oncol 2008; 15: 158-164
85. Tokunaga E, Oki E, Nishida K, et al. Trastuzumab and breast cancer: developments and current status. Int J Clin Oncol 2006; 11: 199-208.
86. Pal S, Saha A, Mohanty K, et al. Generation of Her-2/neu vaccine utilizing idiotypic network cascade. Cancer Biol Ther 2007; 6: 1916-1925
87. Carter P, Presta L, Gorman CM, et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 1992; 89: 4285-4289
88. Mohanty K, Saha A, Pal S, et al. Anti-tumor immunity induced by an anti-idiotype antibody mimicking human Her-2/neu. Breast Cancer Res Treat 2007; 104: 1-11.
89. Clarke GN. Etiology of sperm immunity in women. Fertil Steril. 2008 Feb 15 [Epub ahead of print].
90. Shoenfeld Y, Katz U. IVIg therapy in autoimmunity and related disorders: our experience with a large cohort of patients. Autoimmunity 2005; 38: 123-137 (Pubitemid 40872737)
91. Bayary J, Dasgupta S, Misra N, et al. Intravenous immunoglobulin in autoimmune disorders: an insight into the immunoregulatory mechanisms. Int Immunopharmacol 2006; 6: 528-534
92. Oak S, Gilliam LK, Landin-Olsson M, et al. The lack of anti-idiotypic antibodies, not the presence of the corresponding autoantibodies to glutamate decarboxylase, defines type 1 diabetes. Proc Natl Acad Sci USA 2008; 105: 5471-5476
93. Hall TR, Bogdani M, Leboeuf RC, et al. Modulation of diabetes in NOD mice by GAD65-specific monoclonal antibodies is epitope specific and accompanied by anti-idiotypic antibodies. Immunology 2008; 123: 547-554
94. Lopez-Requena A, Mateo De Acosta C, Vazquez AM, Perez R. Immunogenicity of autologous immunoglobulins: principles and practices. Mol Immunol 2007; 44: 3076-3082 (Pubitemid 46412486)
95. Hernandez T, Lopez-Requena A, De Acosta CM, Mustelier G, Roque-Navarro L, Perez R. B7 and 34B7 monoclonal antibodies: a theoretical approach to the molecular basis of immunoglobulin cross-reactive antibodies. Hybridoma (Larchmt) 2007; 26: 66-72.